PCT Ltd (PCTL)

[Long term]

Consolidated DD & links
ACTION NEEDEDPctl has been trying to get in contact with the government to make them aware of our machine & what it can do
We can help with & in our numbers send them copies of the DD that’s been posted

This is the contact point in government that needs to know about pctl Paradigm Convergence Technology. (Read below)

https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/



Info they’ll need:
PODCAST LINK click
Click in search....Pctl

This is who we can contact in government to make them aware of our machine.

point of entry for the submission of market research packages and meeting requests from interested stakeholders.
The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.
At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development. Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed.
Ideal technologies and products would (but are not required to) be:
* - Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging .Infectious Disease rapid response capabilities
* - Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability
* - Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)

Would you like to meet with a federal agency regarding a product that you are developing for COVID-19?
If you are interested in requesting a CoronaWatch meeting, please Register for an account and Login, or if you have an account Login to submit some basic product information.

Select A portion of this DD ( below dotted line)& send to government site
https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/

PR/heightened demand: https://www.businesswire.com/news/home/20200313005307/en/

Annihilyzer™ system: https://www.youtube.com/watch?v=bZLjJdqpz9s&feature=youtu.be

Paradigm Convergence Technologies Corporation
Summarized Due Diligence Sheet for Investing
[color=red]

ACTION NEEDEDPctl has been trying to get in contact with the government to make them aware of our machine & what it can do
We can help with & in our numbers send them copies of the DD that’s been


This is the contact point in government that needs to know about pctl Paradigm Convergence Technology. (Read below)

https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/



Info they’ll need:

PODCAST LINK click
Click in search....Pctl


Much more DD below dotted line

This is who we can contact in government to make them aware of our machine.

point of entry for the submission of market research packages and meeting requests from interested stakeholders.
The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.
At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development. Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed.
Ideal technologies and products would (but are not required to) be:
* - Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging .Infectious Disease rapid response capabilities
* - Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability
* - Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)

Would you like to meet with a federal agency regarding a product that you are developing for COVID-19?
If you are interested in requesting a CoronaWatch meeting, please Register for an account and Login, or if you have an account Login to submit some basic product information.

===================================================

DD




--GENERAL INFORMATION---

Company Site: para-con.com
Twitter: @PCTL2020
Investor Relations Chesapeake Group - Get on the email list for news [e-mail]

About: a technology licensing company specializing in environmentally safe solutions for global sustainability with products for various markets they serve.

Mission: Infectious Disease and Contamination Control

Markets Served: Hospitals & Healthcare, Agriculture, Oil & Gas, Hotel & Tourism, Food Service/Production

About Products: Products and solutions are designed to take an environmentally conscious approach to combating the spread of infectious disease in the Healthcare and Cleaning industries, as well as contributing to the sustainability of global natural resources in the energy and agriculture markets.

The PCT Annihilyzer® Patented Monitoring, Tracking & Reporting System
The Kiosk, which sits on top of the Filling Station Cabinet, houses The PCT Annihilyzer® System’s computer controls, information system, RFID tagging and reading system and an interactive touch screen display.


---FINANCIAL INFO---

Filings: LINK

Current info as of 3/9/20
Authorized- 1,000,000,000
Outstanding- 511,315,300
Restricted- 35,139,690

Standard Registrar and Transfer Company
440 East 400 South, Suite 200
Salt Lake City, UT 84111
Phone: [phone] or 801-596-2150
www.standardtransferco.com
Amy Merrill Email: [e-mail]


---CURRENT CLIENT LIST---

1: Morgan Stanley Presbyterian Children’s Hospital.
(3959 Broadway At, W 165 St, New York NY 10032)

2: Mount Sinai South Nassau Hospital
(1 Healthy Way, Oceanside NY 11572)

3: Carson Tahoe Regional Medical Center
(1600 Medical Pkwy, Carson City NV 89703)

4: SUNY Downstate Medical Center
(450 Clarkson Ave, Brooklyn NY 11203)

5: Johnston UNC Healthcare Hospital Smithfield
(509 N Brightleaf Blvd , Smithfield, NC 27577)

6: Memorial Sloan Kettering Cancer Center ??? Maybe
(1275 York Avenue New York, NY 10065)

7: North Tees and Hartlepool NHS Foundation Trust, (UK Trial underway began Jan 15th 2020 - 60 day trial)
(University Hospital of Hartlepool, Holdforth Road, Hartlepool, TS24 9AH)
(University Hospital of North Tees, Hardwick, Stockton on Tees, TS19 8PE)

8: New York Presbyterian Columbia Hospital
(Ranked Top 5 in the Nation)
(622 W 168th St, New York NY 10032)
---VP recently endorsed in a LinkedIn post---

9: New York Hospital -- as per PR Release (labeled #1 below)



---PR & RELATED INFORMATION---


1. 03/11/20 - PCT LTD Experiencing Rapid Increase in Interest and Receives Purchase Order from Additional Hospital in New York City PR LINK

2. 03/09/20 - Interview: PCT LTD Hospital Infection Control System installed in seven hospitals and expanding INTERVIEW LINK

3. 02/14/20 - PCT LTD Schedules Investor Call (Call took place on 2/20/20) PR LINK Audio Link (Written Summation below)

4. 01/30/20 - PCT LTD Executes Term Sheet for Debt Financing PR LINK

5. 01/08/20 - PCT LTD Discusses Their International Expansion and Growth Strategy with The Stock Day Podcast PR LINK

6. 12/16/19 - PCT LTD Issues Company Update and Signs Collaborative Agreement for Oil & Gas, and Cannabis Applications PR LINK

7. 10/31/19 - PCT LTD Continues to Expand By Signing Agreement with SUNY Downstate Medical Center Worth over $500,000 PR LINK

8. 10/25/19 - 3rd Quarter 8K released (see above FILINGS link)

9. 10/22/19 - Hospital-acquired Infection Control Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast Period MARKET RESEARCH PR

10. 10/22/19 - PCT LTD Deploys Initial Annihilyzer(R) Infection Control System to the United Kingdom PR LINK

11. 10/4/19 - PCT LTD Announces Additional Hospital Installation of Annihilyzer(R) Infection Control System PR LINK

12. 7/26/19 - The Infection Prevention Strategy is pleased to announce our Top Innovations of the Year: 2019 (Annihilyzer) PR LINK

13. 5/6/2019 - PCT LTD Announces New Purchase Order as the Result of a Successful Trial of Annihilyzer® Infection Control Systems (A TOP 5 hospital in the U.S. AND --#1 in NY-- CONVERTED from Trial to a customer AFTER a successful trial period) - Morgan Stanley Presbyterian Children’s Hospital PR LINK

14. 2/25/19 - PCT LTD Installs a Large Volume Hydrolyte® System with Option Agreement for 4 additional LVH Systems with Oil & Gas Industry Customer PR LINK

15. 1/10/19 - PCT LTD Executes New Master Service Agreement for Installation of Annihilyzer® Hospital Infection Control System at Carson Tahoe Regional Medical Center PR LINK

16. 11/08/18 - PCT LTD Announces Completion of Major Commercialization Milestones and Promotion of Jody Read to CEO Position PR LINK

17. 5/16/18 - Newly Launched Disinfecting System Reduces Hospital Acquired Infections PR LINK

18. 5/10/18 - PCT LTD Receives Patents for RFID Tracking Technology in Cleaning System (US Patent#9679170) PR LINK



----Investor Call Summation, Paradigm Convergeance Technologies Corporation----
---First 10 minutes of call---

---Addressing Financial Filings---

3rd Quarter 10Q
In final review with auditors & SEC Attorneys
Expected to be completed in up to 3 weeks
(updated per IR email--- expected in the next week)

10K
Expected to be filed by April 13th

Convertible Notes
"very active negotiations" to come to a resolve by time of 10K filing (April 13th)

No material change is O/S in months

very actively negotiating financing with negligible, if any, dissolution
No anticipation of R/S

---Growth of about 400% in 2019---
on target to grow exponentially in 2020

G&A down significantly
company become more efficicent, losses narrowed significantly down around 75% from 2018

---Currently Doing---

PCT UK joint venture partner
Trial ongoing: Universities as well as hospitals involved to verify U.S. results
"unless bacteria and virsuses are any different, which they aren't, don't anticipate any difficulty verifying claims"

"Preliminary discussions between PCT UK and National Healthcare system of the UK"

---Markets---
Primary Focus on healthcare sector - hospitals, medical centers assisted living, rehab facilities

Secondarily - Oil & Gas, remidiation of Hydrogen Sulfide (very poisonous, corrosive, and flammable)

Recently - Cannabis Industry - purveyor of service
"Happy to discover our product greatly mitigates or totally elimiants the 3 major problems they are having"

---Current Placement--- (Does not include newest NY Hospital announced above in PR on 3/11/20)
8 hospitals, 11 units installed with "3 more slated in next few weeks with more behind it"


Endorsement from VP of MY Presbyterian
[Suppressed Image]




Not sure how many are aware of BARDA, but I came across a post on Twitter this evening and after doing a little digging, found this:

Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID).

In my eyes that's most certainly an organization that should be aware of the Annihilyzer product, so I connected with their Director, Rick B and provided a post on Linkedin for more exposure to their request of building out a comprehensive portfolio of COVID-19 countermeasures. See below.

(For my privacy, I did redact my information on the image)

Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services

[Suppressed Image]

Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services


UPDATED DUE DILIGENCE 3-17 - RESEARCH NOW
Below is a good portion of the DD done here, by myself and others. Do YOURS now!
(Also pinned on top of board)

Paradigm Convergence Technologies Corporation
Summarized Due Diligence Sheet for Investing


---GENERAL INFORMATION---

Company Site: para-con.com
Twitter: @PCTL2020 - (I urge you to follow them and review their posts)
Investor Relations Chesapeake Group - Get on the email list for news [e-mail]

About: a technology licensing company specializing in environmentally safe solutions for global sustainability with products for various markets they serve.

Mission: Infectious Disease and Contamination Control

Markets Served: Hospitals & Healthcare, Agriculture, Oil & Gas, Hotel & Tourism, Food Service/Production

About Products: Products and solutions are designed to take an environmentally conscious approach to combating the spread of infectious disease in the Healthcare and Cleaning industries, as well as contributing to the sustainability of global natural resources in the energy and agriculture markets.

The PCT Annihilyzer® Patented Monitoring, Tracking & Reporting System
The Kiosk, which sits on top of the Filling Station Cabinet, houses The PCT Annihilyzer® System’s computer controls, information system, RFID tagging and reading system and an interactive touch screen display.


---FINANCIAL INFO---

Filings: LINK

Current info as of 3/9/20
Authorized- 1,000,000,000
Outstanding- 511,315,300
Restricted- 35,139,690

Standard Registrar and Transfer Company
440 East 400 South, Suite 200
Salt Lake City, UT 84111
Phone: [phone] or 801-596-2150
www.standardtransferco.com
Amy Merrill Email: [e-mail]


---CURRENT CLIENT LIST---

1: Morgan Stanley Presbyterian Children’s Hospital.
(3959 Broadway At, W 165 St, New York NY 10032)

2: Mount Sinai South Nassau Hospital
(1 Healthy Way, Oceanside NY 11572)

3: Carson Tahoe Regional Medical Center
(1600 Medical Pkwy, Carson City NV 89703)

4: SUNY Downstate Medical Center
(450 Clarkson Ave, Brooklyn NY 11203)

5: Johnston UNC Healthcare Hospital Smithfield
(509 N Brightleaf Blvd , Smithfield, NC 27577)

6: Memorial Sloan Kettering Cancer Center ??? Maybe
(1275 York Avenue New York, NY 10065)

7: North Tees and Hartlepool NHS Foundation Trust, (UK Trial underway began Jan 15th 2020 - 60 day trial)
(University Hospital of Hartlepool, Holdforth Road, Hartlepool, TS24 9AH)
(University Hospital of North Tees, Hardwick, Stockton on Tees, TS19 8PE)

8: New York Presbyterian Columbia Hospital
(Ranked Top 5 in the Nation)
(622 W 168th St, New York NY 10032)
---VP recently endorsed in a LinkedIn post---

9: New York Hospital -- as per PR Release (labeled #1 below)


---PR & RELATED INFORMATION---

1. 03/18/20 - PCT LTD Receives Large Purchase Order for Recurring Sales of Fluids for Non-Medical Use and Explains Current Revenue Streams PR LINK

2. 03/16/20 - PCT LTD Interview with Stock Day Podcast (MUST LISTEN) PR LINK

3. 03/13/20 - PCT LTD Adds International Distributor and Sells High-Volume Equipment to Existing Customer as a Result of Heightened Demand PR LINK

4. 03/11/20 - PCT LTD Experiencing Rapid Increase in Interest and Receives Purchase Order from Additional Hospital in New York City PR LINK

5. 03/09/20 - Interview: PCT LTD Hospital Infection Control System installed in seven hospitals and expanding INTERVIEW LINK

6. 02/14/20 - PCT LTD Schedules Investor Call (Call took place on 2/20/20) PR LINK Audio Link (Written Summation below)

7. 01/30/20 - PCT LTD Executes Term Sheet for Debt Financing PR LINK

8. 01/08/20 - PCT LTD Discusses Their International Expansion and Growth Strategy with The Stock Day Podcast PR LINK

9. 12/16/19 - PCT LTD Issues Company Update and Signs Collaborative Agreement for Oil & Gas, and Cannabis Applications PR LINK

10. 10/31/19 - PCT LTD Continues to Expand By Signing Agreement with SUNY Downstate Medical Center Worth over $500,000 PR LINK

11. 10/25/19 - 3rd Quarter 8K released (see above FILINGS link)

12. 10/22/19 - Hospital-acquired Infection Control Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast Period MARKET RESEARCH PR

13. 10/22/19 - PCT LTD Deploys Initial Annihilyzer(R) Infection Control System to the United Kingdom PR LINK

14. 10/4/19 - PCT LTD Announces Additional Hospital Installation of Annihilyzer(R) Infection Control System PR LINK

15. 7/26/19 - The Infection Prevention Strategy is pleased to announce our Top Innovations of the Year: 2019 (Annihilyzer) PR LINK

16. 5/6/2019 - PCT LTD Announces New Purchase Order as the Result of a Successful Trial of Annihilyzer® Infection Control Systems (A TOP 5 hospital in the U.S. AND --#1 in NY-- CONVERTED from Trial to a customer AFTER a successful trial period) - Morgan Stanley Presbyterian Children’s Hospital PR LINK

17. 2/25/19 - PCT LTD Installs a Large Volume Hydrolyte® System with Option Agreement for 4 additional LVH Systems with Oil & Gas Industry Customer PR LINK

18. 1/10/19 - PCT LTD Executes New Master Service Agreement for Installation of Annihilyzer® Hospital Infection Control System at Carson Tahoe Regional Medical Center PR LINK

19. 11/08/18 - PCT LTD Announces Completion of Major Commercialization Milestones and Promotion of Jody Read to CEO Position PR LINK

20. 5/16/18 - Newly Launched Disinfecting System Reduces Hospital Acquired Infections PR LINK

21. 5/10/18 - PCT LTD Receives Patents for RFID Tracking Technology in Cleaning System (US Patent#9679170) PR LINK



----Investor Call Summation, Paradigm Convergeance Technologies Corporation----
---First 10 minutes of call---

---Addressing Financial Filings---

3rd Quarter 10Q
In final review with auditors & SEC Attorneys
Expected to be completed in up to 3 weeks
(updated per IR email--- expected in the next week)

10K
Expected to be filed by April 13th

Convertible Notes
"very active negotiations" to come to a resolve by time of 10K filing (April 13th)

No material change is O/S in months

very actively negotiating financing with negligible, if any, dissolution
No anticipation of R/S

---Growth of about 400% in 2019---
on target to grow exponentially in 2020

G&A down significantly
company become more efficicent, losses narrowed significantly down around 75% from 2018

---Currently Doing---

PCT UK joint venture partner
Trial ongoing: Universities as well as hospitals involved to verify U.S. results
"unless bacteria and virsuses are any different, which they aren't, don't anticipate any difficulty verifying claims"

"Preliminary discussions between PCT UK and National Healthcare system of the UK"

---Markets---
Primary Focus on healthcare sector - hospitals, medical centers assisted living, rehab facilities

Secondarily - Oil & Gas, remidiation of Hydrogen Sulfide (very poisonous, corrosive, and flammable)

Recently - Cannabis Industry - purveyor of service
"Happy to discover our product greatly mitigates or totally elimiants the 3 major problems they are having"

---Current Placement--- (Does not include newest NY Hospital announced above in PR on 3/11/20)
8 hospitals, 11 units installed with "3 more slated in next few weeks with more behind it"


Endorsement from VP of MY Presbyterian and other execs
[Suppressed Image]

[Suppressed Image]

[Suppressed Image]

[Suppressed Image]


Not sure how many are aware of BARDA, but I came across a post on Twitter this evening and after doing a little digging, found this:

Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID).

In my eyes that's most certainly an organization that should be aware of the Annihilyzer product, so I connected with their Director, Rick B and provided a post on Linkedin for more exposure to their request of building out a comprehensive portfolio of COVID-19 countermeasures. See below.

(For my privacy, I did redact my information on the image)

Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services

=================
exactly what the EPA said

Quote:

List N includes products that meet EPA’s criteria for use against SARS-CoV-2, the novel coronavirus that causes the disease COVID-19.



The key word here is against The EPA does not come out and say any products on these lists will kill CV-19. However I doubt the EPA would use a strong word as against in the above statement.

Quote:

Note: Inclusion on this list does not constitute an endorsement by EPA. There may be additional disinfectants that meet the criteria for use against SARS-CoV-2. EPA will update this list with additional products as needed.



It's pretty obvious this disclaimer is stating the EPA does not endorse as in recommend any product that's listed. They do not because it would constitute marketing for that product.... The EPA also recognizes that there are other products that meet the criteria against SARS-CV-2 AKA Coronavirus. Why do they make this statement? Because there are other products that are registered with the EPA that are not on this list that meets the criteria against CV-19

Nothing hard to understand there. Here is the a pic of it below:

[Suppressed Image] Of


Lets move on

List N: Disinfectants for Use Against SARS-CoV-2 | Pesticide ...www.epa.gov › pesticide-registration › list-n-disinfectants-use-against-...
If a product qualified for the Emerging Viral Pathogen Claim, it demonstrated efficacy against a harder-to-kill virus than the enveloped human coronavirus

From this statement we know that EXCELYTE which meets this criteria. How do we know this? We know because they are on the N list under EPA registration 92108-1. I also believe this Reg number can be used against the harder to lill Norovirus. Coronavirus is easier to kill than Norovirus. Any amount of basic DD will show that.

Below is the reg and product number for EXCELYTE
[Suppressed Image]

Finally Below is the EPA reg link for EXCELYTE showing it's registered to PCT Ltd. This link is the original registration.

https://iaspub.epa.gov/apex/pesticides/f?p=PPLS:8:1272595636521::NO::P8_PUID,P8_RINUM:513158,92108-1


To wrap it all up is the link to the current N list


https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2